

CTI - Ischaemic Heart Disease January 2010

Adis Clinical Trials Insight: Ongoing Trials Status Tracking – January 2010

The table below highlights the ongoing trials whose status has changed during January 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
1 700043961	APN-01	Completed	I	APN 01: adverse reactions Various toxicities In volunteers	Apeiron Biologics
2 700050440	Aspirin Paclitaxel Prasugrel	Recruiting	IV	Paclitaxel + aspirin +/- prasugrel: therapeutic use Prevention of coronary stent thrombosis Post-Approval trial of the Taxus Liberte paclitaxel-eluting coronary stent system	Boston Scientific Corporation, Daiichi Sankyo Inc, Eli Lilly
3 700047284	Clopidogrel Dexlansoprazole Esomeprazole Lansoprazole Omeprazole	Recruiting	I	Clopidogrel +/- dexlansoprazole, esomeprazole, lansoprazole, omeprazole: pharmacodynamics Effect on steady-state pharmacokinetics and pharmacodynamics of clopidogrel In volunteers	Takeda Global Research and Development Center
4 700051459	Atorvastatin Ezetimibe	Active, no longer recruiting	II	Ezetimibe + atorvastatin: pharmacodynamics Effect on coronary plaque volume In patients with acute coronary syndromes	
5 700024324	Biolimus-A9 Paclitaxel	Completed	III	Biolimus A9 vs paclitaxel: therapeutic use Prevention of coronary artery restenosis	Terumo
6 700018755	Montelukast	Active, no longer recruiting	IV	Montelukast: pharmacodynamics Effects on brachial artery's function In patients with acute coronary syndrome	
7 700042410	Paclitaxel	Active, no longer recruiting	II/III	Paclitaxel: therapeutic use Prevention of coronary artery restenosis Comparing drug eluting balloon vs standard balloon in combination with bare stent and drug eluting stent in patients with complex lesions	
8 700010041	Doxycycline	Completed	II	Doxycycline: therapeutic use Prevention of reperfusion injury In patients undergoing coronary artery bypass graft surgery	
9 700052273	Ciclosporin Tacrolimus Telaprevir	Recruiting	I	Tacrolimus +/- telaprevir, ciclosporin +/- telaprevir: pharmacokinetics Potential pharmacokinetic interactions In volunteers	Tibotec Pharmaceuticals, Vertex

CTI - Ischaemic Heart Disease January 2010



						Pharmaceuticals
Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor	
10 700037439	Aspirin	Active, no longer recruiting	IV	Aspirin: pharmacodynamics Effects of chronic administration on platelet aggregation and thromboxane levels In high-risk subjects		
11 700032379	Clopidogrel	Active, no longer recruiting	IV	Clopidogrel: therapeutic use Prevention of coronary artery restenosis		
12 700033932	Insulin Insulin-glargine Insulin-glulisine	Discontinued	III	Insulin glulisine + insulin glargine vs insulin: pharmacodynamics Effects on infarct size In hyperglycaemic patients with anterior ST elevation myocardial infarction undergoing percutaneous coronary intervention	sanofi-aventis	

For further information, please call +44 (0) 20 7981 0765 or send an e-mail to clientsupport@wolterskluwer.com.